1. Association of PTPN1 polymorphisms with breast cancer risk: A case‐control study in Chinese females. Issue 7 (25th February 2019) Authors: Huang, Shuya; Liu, Liyuan; Xiang, Yujuan; Wang, Fei; Yu, Lixiang; Zhou, Fei; Cui, Shude; Tian, Fuguo; Fan, Zhimin; Geng, Cuizhi; Cao, Xuchen; Yang, Zhenlin; Wang, Xiang; Liang, Hong; Wang, Shu; Jiang, Hongchuan; Duan, Xuening; Wang, Haibo; Li, Guolou; Wang, Qitang Journal: Journal of cellular biochemistry Issue: Volume 120:Issue 7(2019) Page Start: 12039 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study). (May 2023) Authors: Wang, Jiayu; Cai, Li; Song, Yanqiu; Sun, Tao; Tong, Zhongsheng; Teng, Yuee; Li, Huiping; Ouyang, Quchang; Chen, Qianjun; Cui, Shude; Yin, Yongmei; Liao, Ning; Sun, Qiang; Feng, Jifeng; Wang, Xiaojia; Xu, Binghe Journal: European journal of cancer Issue: Volume 184(2023) Page Start: 73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Current Status and Factors Influencing Surgical Options for Breast Cancer in China: A Nationwide Cross‐Sectional Survey of 110 Hospitals. (13th May 2020) Authors: Yang, Benlong; Ren, Guosheng; Song, Erwei; Pan, Da; Zhang, Jing; Wang, Yongsheng; Liao, Ning; Tang, Jinhai; Wang, Xiang; Cui, Shude; Jin, Feng; Geng, Cuizhi; Sun, Qiang; Li, Hongyuan; Fan, Zhimin; Cao, Xuchen; Wang, Haibo; Wang, Shu; Shao, Zhimin; Wu, Jiong Journal: Oncologist Issue: Volume 25:Number 10(2020) Page Start: e1473 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case‐Control Study in Northern and Eastern China and Implications for Chemoprevention. (4th December 2017) Authors: Wang, Fei; Liu, Liyuan; Cui, Shude; Tian, Fuguo; Fan, Zhimin; Geng, Cuizhi; Cao, Xuchen; Yang, Zhenlin; Wang, Xiang; Liang, Hong; Wang, Shu; Jiang, Hongchuan; Duan, Xuening; Wang, Haibo; Li, Guolou; Wang, Qitang; Zhang, Jianguo; Jin, Feng; Tang, Jinhai; Li, Liang Journal: Oncologist Issue: Volume 22:Number 12(2017) Page Start: 1431 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. (May 2019) Authors: Yuan, Peng; Hu, Xichun; Sun, Tao; Li, Wei; Zhang, Qingyuan; Cui, Shude; Cheng, Ying; Ouyang, Quchang; Wang, Xiaojia; Chen, Zhendong; Hiraiwa, Masahide; Saito, Kenichi; Funasaka, Setsuo; Xu, Binghe Journal: European journal of cancer Issue: Volume 112(2019) Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4. (November 2022) Authors: Xu, Binghe; Hu, Xichun; Li, Wei; Sun, Tao; Shen, Kunwei; Wang, Shusen; Cheng, Ying; Zhang, Qingyuan; Cui, Shude; Tong, Zhongsheng; Geng, Cuizhi; Song, Erwei; Huang, Chiun-Sheng; Sriuranpong, Virote; Ngan, Roger K.C.; Chia, Yee H.; Wang, Xinwei; Zhao, Huadong Journal: European journal of cancer Issue: Volume 175(2022) Page Start: 236 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 6 (June 2019) Authors: Jiang, Zefei; Li, Wei; Hu, Xichun; Zhang, Qingyuan; Sun, Tao; Cui, Shude; Wang, Shusen; Ouyang, Quchang; Yin, Yongmei; Geng, Cuizhi; Tong, Zhongsheng; Cheng, Ying; Pan, Yueyin; Sun, Yuping; Wang, Hong; Ouyang, Tao; Gu, Kangsheng; Feng, Jifeng; Wang, Xiaojia; Wang, Shubin Journal: Lancet oncology Issue: Volume 20:Issue 6(2019) Page Start: 806 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study. Issue 21 (May 2018) Authors: Li, Junjie; Shao, Zhimin; Xu, Binghe; Jiang, Zefei; Cui, Shude; Zhang, Jin; Liao, Ning; Jiang, Jun; Wang, Yongsheng; Ouyang, Quchang; Ying, Ziwei Other Names: Talele. Nilesh section editor. Journal: Medicine Issue: Volume 97:Issue 21(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Issue 3 (March 2017) Authors: Zhang, Pin; Sun, Tao; Zhang, Qingyuan; Yuan, Zhongyu; Jiang, Zefei; Wang, Xiao Jia; Cui, Shude; Teng, Yuee; Hu, Xi-Chun; Yang, Junlan; Pan, Hongming; Tong, Zhongsheng; Li, Huiping; Yao, Qiang; Wang, Yongsheng; Yin, Yongmei; Sun, Ping; Zheng, Hong; Cheng, Jing; Lu, Jinsong Journal: Lancet oncology Issue: Volume 18:Issue 3(2017:Mar.) Page Start: 371 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗